Following on from information provided to NICE by the company in September 2017 the appraisal of Mastocytosis (systemic) - masitinib [ID781] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 781 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
| External Assessment Group | Kleijnen Systematic Reviews Ltd |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 December 2022 | Discontinued. Following on from information provided to NICE by the company in September 2017 the appraisal of Mastocytosis (systemic) - masitinib [ID781] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 18 September 2017 | Suspended. The Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for masitinib for treating systematic mastocytosis. Consequently the first appraisal committee discussion of this topic, has been cancelled. We will continue to monitor any developments and will update interested parties if the situation changes. |
| 12 February 2016 | Following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late August 2016 when. The deadline for submissions is expected in approximately late October 2016. |
| 27 November 2015 | Draft scope documents |
| 04 November 2015 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual